People living with myasthenia gravis (MG) have more treatment options today than ever before, and emerging approaches like CAR T-cell therapy could soon add another powerful tool, a neurologist told patients and caregivers at a recent educational event. Even with a growing list of therapies, effective care still…
News
Myasthenia gravis (MG) patients who didn’t have thymus tumors saw reductions in disease severity and medication use two years after undergoing a type of minimally invasive thymectomy (surgery to remove the thymus gland), a study showed. Most of the 33…
An experimental cell therapy designed to selectively eliminate immune cells that produce the most common disease-driving antibodies in myasthenia gravis (MG) showed promise in laboratory and mouse models. The treatment involves engineering immune T-cells to selectively kill B-cells producing self-reactive antibodies (autoantibodies) against the…
Thymectomy — a surgery to remove the thymus gland — can help keep generalized myasthenia gravis (gMG) under control while decreasing the need for immunosuppressive medications in both younger and older patients without a thymus tumor, a study found. “These findings provide some support to the use of…
One year of treatment with Ultomiris (ravulizumab-cwvz) was associated with reduced fatigue and improved quality of life for three older adults with generalized myasthenia gravis (gMG), according to a small study in Italy. While all three patients experienced less muscle weakness and fewer daily struggles, changes in cognitive…
Mindy Henderson has spent much of her life challenging the limits others have placed on her. When she was diagnosed with spinal muscular atrophy (SMA) — a genetic condition that causes muscles to weaken over time — as an infant, doctors told her parents that she might not live long…
Measuring the percentage of CD3-positive T cells in the blood after thymectomy, or surgical removal of the thymus, may help identify recurrence risk in people with myasthenia gravis (MG) who do not have a thymoma, or thymus tumor, a study suggests. Data from 275 patients showed that those…
The investigational CAR T-cell therapy KYV-101, or mivocabtagene autoleucel (miv-cel), improves muscle strength and daily functioning in people with hard-to-treat generalized myasthenia gravis (gMG), with benefits lasting for up to two years after dosing. That’s according to data from three patients with self-reactive antibodies against acetylcholine receptors (AChR),…
Vyvgart (efgartigimod alfa) is generally well tolerated and effective for adults with generalized myasthenia gravis (gMG), regardless of the presence and type of disease-causing antibody, according to a real-world study in Japan. The treatment, which has been approved in Japan for gMG regardless of antibody status since 2022 and…
A prefilled syringe and an autoinjector used to deliver gefurulimab, an experimental therapy in late-stage development for generalized myasthenia gravis (gMG), can be safely and effectively used by most gMG patients, caregivers, and healthcare professionals. That’s according to a simulated-use study, which aims to assess if people can…
Recent Posts
- Real-world use of gMG treatment in US mirrors patterns seen in trials
- Can you love someone without being their caregiver? I say, yes, you can.
- Early IgG drops may signal response to generalized MG therapy, study finds
- Guest Voice: I have MG, but my daughter and I are in it together
- Study ties sexual problems in MG to nerve issues